CollectiveClaim.us

About CollectiveClaim.us

Tue, 13 Oct 2026 00:00:00 +0530

CollectiveClaim.us is an independent legal-information publisher and a mass tort marketing and inquiry service. We do two things:

We publish. Sourced, plain-language writing about litigation and regulation in the United States: mass torts, product liability, pharmaceutical and medical device cases, environmental exposure claims, class actions, and the procedure that holds them together.
We connect. If you tell us what happened to you, we pass your inquiry to law firms that handle mass tort and related claims and may be able to review it. That part is a commercial service: we are not a law firm, we do not give legal advice, we do not review claims ourselves, and we may be paid by the firms that receive inquiries.

No inquiry is a case, and sending one does not create an attorney-client relationship or entitle anyone to compensation. Whether a claim exists, what it is worth and what to file are questions only a licensed lawyer in the relevant state can answer. The disclaimer sets out the limits, and the contact page explains exactly what happens after you send an inquiry.

Acetaminophen and Autism Claims: What MDL 3043 Shows

Tue, 13 Oct 2026 00:00:00 +0530

Acetaminophen is the active ingredient in Tylenol and in many other pain, fever and cold products sold in the United States. Since 2022, federal lawsuits have alleged that use of acetaminophen during pregnancy caused children to develop autism spectrum disorder (ASD) or attention deficit/hyperactivity disorder (ADHD). The cases are consolidated in the Southern District of New York as MDL No. 3043, before Judge Denise L. Cote. The Judicial Panel on Multidistrict Litigation’s October 1, 2026 statistics report lists 113 actions pending, out of 777 filed in total. The court has dismissed parts of the claims and has excluded the plaintiffs’ causation experts, and no court has found that acetaminophen caused any child’s condition.

Advertising Policy

Tue, 13 Oct 2026 00:00:00 +0530

Who serves the advertising

Advertising on this site is served by Google AdSense. No advertising is displayed until the site’s AdSense account has been approved and a publisher identifier is configured; until then these pages disclose what will run, and no ad code, ad cookie or ad request is present. The ads are selected by Google’s systems, not by us: we do not choose them, we do not sell space to a particular advertiser, and we do not know which advert you will see. We receive aggregate reporting only.

AFFF and PFAS Firefighting Foam Litigation: MDL 2873 Status

Tue, 13 Oct 2026 00:00:00 +0530

Aqueous film-forming foam (AFFF) is a firefighting foam used for decades at airports, military bases and industrial sites. Its PFAS content, chiefly PFOS and PFOA, is the subject of MDL 2873, a federal multidistrict proceeding with more than 15,000 pending actions. The Judicial Panel on Multidistrict Litigation created the MDL in 2018 and assigned it to Judge Richard M. Gergel in the District of South Carolina. Class settlements with 3M and with DuPont, Chemours and Corteva, covering public water systems rather than individuals, received final approval in 2024. Claims by firefighters, service members and residents alleging personal injury from exposure remain unresolved by any global settlement, and no court has decided that AFFF exposure caused any individual’s disease.

Asbestos and Mesothelioma Claims: What the Litigation Record Shows

Tue, 13 Oct 2026 00:00:00 +0530

Asbestos is a naturally occurring mineral fiber that US agencies classify as a known human carcinogen. Inhaling asbestos fibers can cause mesothelioma, a cancer of the thin membranes lining the chest and abdomen, along with cancers of the lung, larynx and ovary and the non-cancerous lung disease asbestosis. The legal response has no single ending: claims have been filed in US courts since the 1960s, many manufacturers resolved liability through bankruptcy trusts, and the federal courts have not handled asbestos claims in one continuing consolidated proceeding. The agency record establishes that asbestos causes disease. In the sources cited here, no court has decided that any individual defendant’s product caused any individual person’s illness.

Boy Scouts Abuse Settlement: How the Survivor Trust Works

Tue, 13 Oct 2026 00:00:00 +0530

The Boy Scouts of America and Delaware BSA, LLC filed for chapter 11 protection on February 18, 2020 in the U.S. Bankruptcy Court for the District of Delaware, case no. 20-10343. By the November 16, 2020 bar date, creditors had filed more than 100,000 proofs of claim, of which 82,209 were unique and timely claims of sexual abuse. The court confirmed a reorganization plan on September 8, 2022, and it took effect on April 19, 2023, creating the Scouting Settlement Trust to evaluate and pay abuse claims. In February 2026 the trust said it can pay 4.7 percent of each allowed claim amount. Undecided: how much more any claimant will receive, and how the bankruptcy judge resolves a dispute over funds reserved for claims by people who were minors when BSA filed.

Catholic Church Abuse Claims: Diocesan Bankruptcy and Trusts

Tue, 13 Oct 2026 00:00:00 +0530

Many claims over child sexual abuse by Catholic clergy in the United States are now resolved inside federal bankruptcy courts rather than by juries. Dioceses and archdioceses have filed for Chapter 11 after states opened or revived windows for time-barred lawsuits; the court sets a claim deadline, a committee represents survivors, and a confirmed plan usually channels claims into a trust. Outcomes differ: Camden, New Jersey has a confirmed plan and funded trust plus a further settlement announced in 2026, Rockville Centre, New York added 136 parishes as debtors, and Oakland, California has had its plan rejected as presented. Each case is separate, and filing is not a finding of liability.

CollectiveClaim Editorial Desk

Tue, 13 Oct 2026 00:00:00 +0530

The CollectiveClaim Editorial Desk writes, sources and fact-checks every article published here. It is an internal function rather than an individual byline, because we do not attach personal names or credentials to work unless those credentials can be verified by a reader.

Commercial Truck Collision Claims: How the Law Actually Works

Tue, 13 Oct 2026 00:00:00 +0530

A commercial truck collision claim is an ordinary personal injury lawsuit, not a mass tort. The injured person sues the driver and usually the motor carrier that employed the driver, and a court decides whether negligence caused that one crash. There is no national multidistrict litigation and no class action covering truck crashes generally, because each crash is a separate event with its own facts. Federal agencies publish crash statistics and set safety rules for carriers and drivers, but neither the Federal Motor Carrier Safety Administration (FMCSA) nor the National Highway Traffic Safety Administration (NHTSA) decides who was at fault in a particular collision.

Contact the Editorial Desk

Tue, 13 Oct 2026 00:00:00 +0530

Email the editorial desk at editorial@collectiveclaim.us, or use the form at the bottom of this page. Messages are read by the people who write and check the articles, not by an agency and not by a chatbot.

What we can help with

Corrections and factual disputes. Tell us the article, the specific statement, and the document that contradicts it. The corrections policy explains what happens next.
Source submissions. If you have a court filing, agency document, settlement notice or statute we should be working from, send the link or the PDF.
Press and research enquiries. We will say what we can and cannot substantiate.

What we cannot help with

Legal advice. We are a publication, not a law firm, and we cannot tell you whether you have a claim, what it is worth, or what to file.
Advice about your own case. We can pass an inquiry to a law firm, but we cannot tell you whether you have a claim, what it is worth or what to file, and nothing we send you is legal advice.
Deadlines on your behalf. If you have received a court-approved settlement notice, the deadline in that notice is set by the court. Only the court-appointed administrator can tell you whether a claim was received. The sources and verification guide explains how to identify the genuine administrator.

If you cannot reach us

For anything time-critical about a legal deadline, contact a lawyer or the court directly, not a website that forwards inquiries.

Cookie Policy

Tue, 13 Oct 2026 00:00:00 +0530

The short version

This site sets no cookies of its own. It has no analytics, no tag manager, no social embeds and no tracking pixels. The only cookies you may receive here come from advertising served by Google AdSense, and those only exist while advertising is enabled. You can block or delete them at any time, and the site keeps working without them.

Copyright and Takedown Policy

Tue, 13 Oct 2026 00:00:00 +0530

Our own material

The text, layout and graphics on this site are the publication’s own work unless stated otherwise. Court filings, statutes, agency documents and other government material we describe or quote are public records, and our description of them is our own wording with the original source linked.

Corrections Policy

Tue, 13 Oct 2026 00:00:00 +0530

How to report an error

Email editorial@collectiveclaim.us with: the article URL, the exact sentence or figure, and the document that shows what is correct. A link to a court docket, an agency page, a statute or an official settlement notice is enough; you do not need to be a party to the case or a lawyer to report an error.

Depo-Provera and Meningioma Claims: What the Record Shows

Tue, 13 Oct 2026 00:00:00 +0530

Depo-Provera is an injectable contraceptive containing medroxyprogesterone acetate, given by intramuscular injection every three months. In December 2025 the FDA approved a labeling supplement adding meningioma, a tumor in the membranes around the brain and spinal cord, to the product’s warnings and patient information. Federal lawsuits alleging that long-term use caused meningiomas were consolidated in February 2025 into MDL No. 3140 in the Northern District of Florida, where thousands of actions are pending and a settlement of a majority of the claims is being administered. No court has determined that the drug caused any individual’s meningioma; the central causation questions were briefed and set for a hearing, not decided.

Disclaimer

Tue, 13 Oct 2026 00:00:00 +0530

CollectiveClaim.us publishes general legal information. It is not a law firm and does not provide legal advice.

What this means in practice

Nothing on this site is advice about your situation. Legal outcomes depend on facts, documents, deadlines and jurisdiction-specific rules that a website cannot know.
Reading this site, quoting it, or emailing the editorial desk does not create an attorney-client relationship with anyone.
We do not tell readers whether they have a claim, what a claim is worth, or what to file. We do not practise law. If you send an inquiry we may pass it to law firms that handle the relevant category of case, and we may be paid for doing so; those firms decide for themselves whether to respond and whether to take a matter.

About what you read here

Reported allegations are allegations. Pages describing complaints, notices or investigations report what has been asserted, attributed to the filing or the party that asserted it. An allegation is not a finding.
Court rulings, verdicts, regulatory actions and settlements are described as such, with the court or agency and the date named. Where an appeal, post-trial motion or approval step is pending, the page says so.
Settlements and claim deadlines come from the court or the official administrator. If those conflict with anything on this site, the court notice governs. Deadlines in a settlement notice are court-ordered and are not extended because a website described them differently.
Legal information changes. Statutes are amended, panels transfer cases, agencies revise guidance. Pages carry publication and review dates, but you should verify current status against the primary record before acting.

Sensitive matters

Some topics here involve serious harm, including child sexual abuse. Articles in this area describe the legal framework and the public record. If reading this material is distressing, support services in the United States include the National Sexual Assault Hotline (RAINN, 800-656-4673) and the 988 Suicide & Crisis Lifeline. These are independent services, not affiliated with this publication.

Documenting a Product Injury Claim: What to Keep, and Where to Report It

Tue, 13 Oct 2026 00:00:00 +0530

Product liability cases are decided on documents, and the documents are easiest to collect in the days after an injury rather than months later. This guide covers what to preserve, what to report, and where the agencies’ own systems fit in. It is about creating a reliable record; it is not advice on whether you have a claim, and it does not tell you what to file.

Editorial Policy

Tue, 13 Oct 2026 00:00:00 +0530

This page sets out the standards every article on CollectiveClaim.us is held to. It is written so it can be checked against the published articles rather than taken on trust.

1. What we publish

General legal information for a United States audience: what a regulator, court, legislature or settlement administrator has done, how a procedural rule operates, and what remains undecided in a live dispute. We do not publish individualised advice, and no article is written as if the reader’s facts were known to us.

Frequently Asked Questions

Tue, 13 Oct 2026 00:00:00 +0530

These answers cover the questions readers ask most often about the subject matter on this site and about how the publication works. They are general information, not advice about any individual matter; the disclaimer explains the limits, and the contact page explains what the editorial desk can and cannot do.

GLP-1 Lawsuits (Ozempic and Wegovy): What the Record Shows

Tue, 13 Oct 2026 00:00:00 +0530

Glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, are a class of prescription medicines approved in the United States to treat type 2 diabetes, obesity, or both. Under brand names that include Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound, they have become some of the most widely prescribed drugs in the country, and personal-injury lawsuits alleging side effects have followed. Federal claims that the medicines cause gastrointestinal injuries were consolidated into MDL No. 3094 in the Eastern District of Pennsylvania, which the Judicial Panel on Multidistrict Litigation reported at 4,025 pending actions as of October 1, 2026. A second federal proceeding, MDL No. 3163, consolidates claims of an eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). No court has determined that any GLP-1 RA caused an individual patient’s injury.

Hernia Mesh Litigation: What the Court and FDA Records Show

Tue, 13 Oct 2026 00:00:00 +0530

Federal lawsuits alleging that polypropylene hernia mesh made by Davol Inc. and C.R. Bard Inc. (now part of Becton Dickinson, or BD) caused complications such as adhesions, organ damage, mesh migration and infection were consolidated into one federal proceeding in 2018. That proceeding is MDL 2846, assigned to Judge Edmund A. Sargus Jr. in the U.S. District Court for the Southern District of Ohio, and the Judicial Panel on Multidistrict Litigation (JPML) counted 23,324 actions pending there as of October 1, 2026. In October 2024 BD announced an agreement to resolve the vast majority of that litigation without admitting liability and without disclosing the terms. No court has found that any mesh product caused any individual patient’s injury.